NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Sammaan For All is excited to announce the return of Diwali at Times Square presented by P&G and Tide and Toyota on October 24, 2026, at the Center of the Universe. Diwali at Times Square continues to convey the true meaning of Diwali by spreading the message of love, peace, harmony and togetherness.

The Consulate General of India in New York hosted a press conference on October 14, 2026, where Deputy Consul General Vishal Harsh extended his warm support to the festival celebrations.

Ambassador Binaya S. Pradhan, Consul General of India in New York, in his message, said that "Diwali celebrates the triumph of light over darkness, knowledge over ignorance, and hope over despair. I commend Samman For All-Diwali At Times Square for bringing communities together in one of the world's most iconic public spaces to share the joy of this festival. May this celebration deepen the bonds of friendship between India and the United States; between all communities, and inspire us all to build a more compassionate and inclusive world."

Neeta Bhasin also acknowledged the Office of Community Engagement of NYC for its continued support of Diwali at Times Square's mission to celebrate the diversity of South Asia and America.

Neeta Bhasin shared the program for the upcoming celebration, starting with an Awards and Gala Dinner on October 23, 2026, at Tribeca 360, where the incredible contributions of Indian Americans in the fields of philanthropy, innovation, medicine and entrepreneurship will be honored. The gala will be followed by the Diwali at Times Square festival on October 24, 2026, bringing communities of all backgrounds together in the heart of New York City.

The festival on October 24, 2026, will feature a vibrant and engaging Diwali Bazaar as well as a dedicated Kids Zone, where children can paint diyas, create colorful rangoli art and enjoy

Bollywood dance lessons. Additionally, attendees can look forward to product sampling from vendors, educational information from partners and much more to ensure a fun-filled day for all.

The afternoon will feature the 'Colors of India and America' program, showcasing spectacular performances by Indian, Indo-Caribbean and Hispanic dance groups celebrating the festival's spirit of diversity and inclusion. In the evening, dignitaries will join together for a special Diya Lighting Ceremony with a countdown on the Ball Drop Tower screen, leading into the Light Up Times Square Concert.

The performance lineup for the 11th edition of the Diwali at Times Square concert was officially announced. The celebration will feature an exceptional mix of celebrated artists and rising stars, including Kanika Kapoor, the Filmfare Award-winning voice behind some of Bollywood's most loved dance anthems. Joining her will be Grammy-nominated Indian American rapper Raja Kumari, who continues to bring Indian art, culture and spirituality to the world stage, along with Indian Idol 13 winner Rishi Singh and Indian Idol 12 finalist Shanmukha Priya. The lineup will also feature singer-rapper and Guinness World Record holder Sparsh Shah, known as "Purhythm," New York's 'Singing Chef' Kunal Lamba and New Jersey's rising star Saanvi Nacha.

We extend our gratitude to our Presenting Sponsors, P&G and Tide and Toyota; our Platinum Sponsor, Gopi; our Gold Sponsor, Xoom by PayPal; our other key sponsors, State Bank of India; and our Media Partner, Colors TV, which will broadcast the festival on its channel. Their partnerships have been instrumental in bringing this vibrant festival to life and sharing the spirit of Diwali with the community.

'Toyota is proud to partner with Diwali at Times Square, celebrating the rich traditions, diverse experiences, and aspirations of the Indian American community. We believe in recognizing and celebrating every side of who you are, and in building meaningful connections that reflect the many ways Indians are living, growing, and expressing themselves. - Tiffany Shido, General Manager, Brand, Cross-Vehicle Line & Media, Toyota Marketing

We are deeply honored to participate in the iconic Diwali at Times Square celebration, the most vibrant and recognized festival celebrating Indian culture on the global stage. Diwali is a festival of light, hope, and togetherness - values that resonate at the heart of everything GOPI does. As a trusted dairy brand, we are proud to celebrate this sacred occasion alongside thousands of families and community members who gather to honor our shared cultural traditions. Through our participation, we reaffirm our commitment to bringing the goodness of pure, authentic ingredients to communities across the country."

"Diwali is a powerful celebration of light, hope, and community - values that resonate deeply with us at Xoom. We are proud to sponsor Diwali at Times Square and stand alongside the Indian community in honoring its rich traditions and culture. Being part of this special celebration strengthens our connection with the community and reflects our commitment to helping people stay connected to the loved ones, places, and traditions that matter most."

Neeta Bhasin the founder and creator of Diwali at Times Square expressed, "As we begin a new decade of Diwali at Times Square, we carry forward the light that our community and our partners have shared with us over the years. It is so important to instill in South Asian American youth a sense of pride in their heritage, and to show the world the values of art, culture and togetherness that Diwali stands for."

Lights shine brighter when we shine together.

For information on the festival, please contact:

- Phone: 212-216-9305 / 516-343-0181

- Email: [email protected]

- Website: www.diwalitimessquare.com

SOURCE Diwali at Times Square

Share this article

WASHINGTON, Oct. 19, 2026 /PRNewswire/ -- USA News Group News Commentary - Ukrainian President Volodymyr Zelenskyy said on Saturday that tests showed Starlink-equipped drones lost their connection when flying faster than about 100 mph inside Ukraine, while Starlink terminals moving at more than 112 mph inside the European Union worked normally. "In other words, this is a planned operation," he said. No one in Washington or at SpaceX has claimed the decision. Most U.S.-listed space stocks fell sharply last week, while Europe's only low Earth orbit broadband rival to SpaceX had its best day in 16 months. Active Companies from around the markets with current developments this week include: Space Exploration Technologies Corp. (NASDAQ: SPCX), AST SpaceMobile, Inc. (NASDAQ: ASTS), Iridium Communications Inc. (NASDAQ: IRDM), Rocket Lab Corporation (NASDAQ: RKLB), Eutelsat Communications SA (Euronext Paris: ETL).

The restrictions reportedly cover both Starlink and Starshield, SpaceX's military-use service, which Ukraine relies on for communications, logistics, live drone video and targeting. The Telegraph reported on Oct. 16, citing four unnamed sources, that Elon Musk approached President Trump with the idea of slowing Starlink in Ukraine and that Trump "agreed." Musk said on X that speed or usage limits on Starshield "are decided by the US military and ultimately POTUS." Trump told reporters, "it wasn't me, and I don't think it was Elon."

Secretary of State Marco Rubio said on Saturday, "We had nothing to do with it. Nobody ordered that Starlink speed to be slowed down. It sorta happened." He also said Starshield was not available to Ukraine, which Yahoo Finance noted conflicts with a late 2024 Pentagon contract that expanded Ukraine's Starshield access from about 500 to roughly 3,000 terminals. Speaking on NBC's Meet the Press on Sunday, Zelenskyy said, "Just give us back Starlink."

Europe is paying close attention. The European Union is working to develop its own alternative to Starlink, and on Sunday the U.S. ambassador to the EU threatened "devastating" retaliation if the bloc advanced a proposal favoring EU-made satellites over companies like SpaceX, Yahoo Finance reported.

CONTINUED... Read this and more news for the space sector at: usanewsgroup.com

In other industry developments and happenings in the market this week include:

Space Exploration Technologies Corp. (NASDAQ: SPCX)

Shares of SpaceX fell 10.17% last week, from $162.57 at the Oct. 9 close to $146.03 on Oct. 16, according to Stock Analysis data, though they remain above the $135 price of the company's June initial public offering. Starlink, a core part of SpaceX's business, has more than 13 million subscribers worldwide, and Yahoo Finance noted this is the first throttling episode since the company went public.

SpaceX has limited service in Ukraine before. In 2023, President and COO Gwynne Shotwell acknowledged the company could restrict how Ukraine used Starlink, saying, "There are things that we can do, and have done." Musk said on X last week that Starlink "is limited to civilian or defensive activities."

AST SpaceMobile, Inc. (NASDAQ: ASTS)

AST SpaceMobile, which is building a space-based cellular broadband network that connects directly to standard smartphones, fell 20.23% last week, from $50.97 to $40.66. On Oct. 13, Piper Sandler downgraded the stock to Neutral from Overweight and cut its price target to $54 from $98, citing SpaceX's direct-to-cell ambitions after its agreement to acquire Grain Management's 800 MHz spectrum for about $8 billion, subject to regulatory approval.

Piper warned that SpaceX could, in theory, limit launch opportunities for competitors such as AST and pressure pricing by competing with telecom operators. Not every analyst agreed. Deutsche Bank upgraded the shares to Buy on Oct. 12 with a $93 target, and Clear Street reiterated a Buy rating with a $115 target, arguing AST is about six months ahead of SpaceX in direct-to-cell.

Iridium Communications Inc. (NASDAQ: IRDM)

Iridium announced on Oct. 14 that Altair Semiconductor is adding Iridium NTN Direct to its ALT1350 and ALT1550 cellular IoT chipsets, letting device makers, module makers and mobile network operators add satellite coverage without a separate satellite modem. "Iridium is offering device manufacturers a powerful new way to develop connected products," said Tim Last, executive vice president at Iridium.

Iridium stockholders approved the company's acquisition by Rocket Lab on Sept. 24, with about 99.6% of votes cast in favor. Each Iridium share is to be exchanged for $27.00 in cash plus Rocket Lab stock based on an exchange ratio subject to a collar, for a notional value of $54.00 per share, and the deal is expected to close by mid-2027, subject to remaining regulatory approvals. Iridium shares fell 7.82% last week, from $47.47 to $43.76.

Rocket Lab Corporation (NASDAQ: RKLB)

Rocket Lab shares fell 25.47% last week, from $68.21 to $50.84, after founder and CEO Sir Peter Beck said in a video posted to YouTube that the first launch of the company's Neutron rocket would move from late 2026 into 2027. Inspectors found voids in the carbon-fiber layers of a recently made forward propellant dome after curing, according to Space.com.

Beck said the voids "don't necessarily mean that the dome would fail in flight," but added, "Possible success isn't our standard." Rocket Lab expects to finish a new forward dome by the end of the year and complete first-stage testing in the first quarter of 2027, after which Beck said the company expects to be "in good shape to share a new target launch date."

Eutelsat Communications SA (Euronext Paris: ETL)

Eutelsat shares jumped 23% on Oct. 14, the stock's biggest one-day gain in 16 months, Reuters reported, after Ukraine said Starlink had introduced restrictions on its military-grade service. Eutelsat's OneWeb network has more than 600 satellites in low Earth orbit, compared with about 10,000 for Starlink, and it is the only company besides SpaceX providing space-based internet through a low Earth orbit network. Bernstein analyst Aleksander Peterc said the news put European providers "back in the spotlight as potential alternatives."

Not everyone sees an easy swap. Existing Starlink users cannot simply switch to OneWeb, since a transition would require new terminals and supporting infrastructure, and independent consultant Christian Freiherr von der Ropp said "considering it as a straightforward substitute overlooks significant operational and infrastructure constraints."

Space stocks swung hard on headlines last week. Learn to read the charts behind moves like these with the free Stock Preachers guide, plus The Roadmap market reports, at stockpreachers.com.

Contact Information:

usanewsgroup.com

Media Contact: [email protected]

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is not a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

This article is independent news commentary. USA News Group is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. MEL has not been paid by any company mentioned in this article. MEL and its owners, operators, directors, and affiliates do not currently own any shares of the companies mentioned in this article, but reserve the right to, and will, buy and sell shares of those companies at any time without further notice. Weekly price changes are from the October 9, 2026 close to the October 16, 2026 close based on Stock Analysis data. Information is drawn from company news releases, published reporting and third-party data believed to be reliable, but its accuracy is not guaranteed. Investing in securities carries risk, including the loss of some or all of your investment. This document is governed by the laws of Ireland.

SOURCE USA News Group

Share this article

Babiec will help to accelerate VIA's mission to secure data and AI for community safety, resilience, and prosperity.

BOSTON, Oct. 19, 2026 /PRNewswire/ -- VIA Science, Inc. (VIA), a leading software provider to defense, law enforcement, and humanitarian organizations, today announced the appointment of Joe Babiec as Chief Mission Officer. Babiec, who joined VIA in 2018 and was most recently VIA's Chief Commercial Officer, will now lead efforts to accelerate VIA's mission impact with its customers and the communities it serves.

As Chief Mission Officer, Babiec will accelerate VIA's effectiveness both internally and externally. Internally, he will ensure VIA's customer and partner decisions support the company's mission to secure data and AI for community safety, resilience, and prosperity. Externally, Babiec will raise awareness of VIA's impact as the company rapidly scales across the globe.

"Joe brings a rare combination of commercial and public policy experience along with an understanding of the consequences technologies can have for communities. He embodies a key VIA value of 'respect a challenge and challenge with respect," said Colin Gounden, co-founder and CEO of VIA. "This newly created role gives Joe the mandate to ensure we live up to our 'no compromise' ethos in the increasingly complex and volatile markets in which we operate. He will also help us convey the impact of our work to the policymakers, industry leaders, and the communities VIA supports."

Babiec is excited to take on this leadership challenge. "I've been fortunate in my career to help many organizations align mission, strategy, and operations to achieve positive outcomes in the communities they serve. As VIA's Chief Mission Officer, I'm grateful to be working in partnership with premier organizations to address some of the world's most pressing challenges through the responsible use of artificial intelligence and other advanced digital technologies."

Babiec has three decades of experience as a strategic advisor, an entrepreneur, an early-stage venture investor, and a private equity company board member. Babiec has worked extensively with senior corporate, government, non-profit, labor, media, and other stakeholders in the U.S. and globally. Joe is a graduate of the Massachusetts Institute of Technology and the London School of Economics.

About VIA

Headquartered in Boston, VIA provides mission-critical software for secure data exchange and trustworthy AI without compromising speed, simplicity, or resilience. Its military-grade architecture helps defense, public safety agencies, and humanitarian organizations use AI while maintaining control of sensitive, distributed data even in contested or offline environments.

SOURCE VIA Science, Inc.

Share this article

- New data revealed at PACK EXPO finds U.S. consumer packaged goods (CPG) and life sciences manufacturers are adopting AI faster than their global peers

- Schneider Electric spotlights how digital and open automation tech establish the foundation for AI-enabled, connected manufacturing

CHICAGO, Oct. 19, 2026 /PRNewswire/ -- Schneider Electric, a global energy technology leader, today revealed new data showcasing that U.S. CPG and life sciences manufacturers are leading in industrial AI adoption globally at PACK EXPO International 2026. Throughout the event, Schneider Electric will discuss how industrial intelligence solutions and open, software-defined automation help manufacturers establish an AI-enabled foundation to improve productivity, increase operational flexibility, and build more connected, resilient operations amid the rise in industrial AI adoption.

Manufacturers in the consumer-packaged goods (CPG) and packaging industries face rising customer expectations, market volatility, workforce challenges, and ongoing pressure to improve efficiency. As an automation and energy tech partner, Schneider Electric will host engagements throughout the week to showcase how automation, electrification, software, and data can work together to help address these challenges and create more flexible, future-ready operations.

"Manufacturers are being asked to increase productivity, adapt faster, and do more with the resources they have," said Greg Magdanz, Vice President of OEM Sales, Schneider Electric. "U.S. CPG and life sciences manufacturers are leading their global peers in adopting next-generation technologies at scale, and our data confirms that momentum. By connecting automation, data, and digital technologies, manufacturers can convert early AI adoption into production efficiencies, stronger operational resilience, and better outcomes for their customers."

Supplementing the company's previous global Beyond the Hype: Practical AI for Competitive Consumer Goods Manufacturing are newly released insights from a representative survey conducted by Censuswide of 252 senior manufacturing decisionmakers, which shows the pace of U.S. AI adoption and the operational pressures driving investment:

- AI is already more deeply embedded in U.S. operations. Among 1,400+ executives surveyed worldwide, 13% of global CPG manufacturers say AI is embedded end to end in core operations and decision-making today, compared with 29% in the U.S.—more than twice the global figure.

- In the U.S., 52% of CPG manufacturers have deployed AI across multiple sites or processes, compared with 27% globally.

- By 2030, 67% of U.S. respondents expect AI to be core to their operations, compared with 37% of respondents globally.

- Operational losses are higher in the U.S. U.S. CPG manufacturers estimate that downtime, waste, delays, rework, and suboptimal asset use cost them 20% of potential manufacturing revenue, compared with a 15% global average.

- Those losses are expected to rise to 27% in the U.S. by 2027, compared with 21% globally, and to 34% by 2030, compared with 29% globally — signaling growing cost pressure and operational fragility.

The findings reveal that U.S. manufacturers are moving faster on AI. At the same time, they face greater exposure to operational losses as domestic labor shortages, aging infrastructure, and higher compliance burdens intensify the pressure. To capture the full value of AI, manufacturers must pair AI adoption with foundational investments in connected, contextualized data, open automation and industrial intelligence solutions that turn insight into action and enable continuous innovation. This pathway to future-proofing operations is exactly what Schneider Electric will address during the "Open, Connected, and Human-Centered: The Future of Industrial Operations" session on Sunday, October 18 — and in conversations throughout PACK EXPO International 2026. Through its extensive network of OEMs, Machine Builders and Alliance Partners, Schneider Electric connects technology with deep application expertise, helping manufacturers turn innovation into smarter machines, more adaptable production, and measurable operational outcomes.

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability. The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world's most sustainable companies.

Follow us on: Twitter | Facebook | LinkedIn | YouTube | Instagram | Blog

Learn more about Advancing Energy Tech on Schneider Electric Insights.

SOURCE Schneider Electric

Share this article

Understanding What Affects How Long a Roof Lasts in Michigan Helps Homeowners Plan Ahead and Avoid Costly Emergency Replacements

GRAND HAVEN, Mich., Oct. 19, 2026 /PRNewswire/ -- How long should a roof last in Michigan, and what factors most affect that timeline? HelloNation has published an article that answers this question and explains what homeowners need to know about roof lifespan Michigan weather conditions and installation quality directly influence.

The HelloNation article explains that asphalt shingles are the most common roofing material in Michigan, and under good conditions with proper installation and adequate ventilation, they typically last between 20 and 30 years. Three-tab shingles tend to land at the lower end of that range. Architectural shingles, which are thicker and more durable, often perform closer to the 25- to 30-year mark.

Installation quality has a significant effect on how long a roof holds up. The article notes that shingles that were not properly fastened, or that were installed without adequate underlayment, are more vulnerable to wind and water intrusion from the start. A roof installed correctly by an experienced contractor will almost always outlast one that was done quickly or at reduced cost, even when the materials are identical.

Ventilation is described in the article as one of the most overlooked factors in roof lifespan Michigan homeowners should pay attention to. When attic heat has no path to escape, it builds up and bakes the shingles from below. In summer, this accelerates the breakdown of the asphalt and causes shingles to crack, curl, or blister ahead of schedule. Proper ridge and soffit ventilation keeps attic temperatures lower and dramatically extends the life of the roofing materials above.

Ice dams are covered in the article as a specific and recurring threat in Grand Haven and across West Michigan. They form when heat escaping through the roof melts snow near the peak, and that meltwater refreezes as it reaches the colder eaves. The article notes that ice dams Grand Haven homeowners deal with over multiple winters can saturate the decking, damage the underlayment, and cause leaks that are difficult to trace back to their source.

Storm damage is another factor the article addresses. A severe hailstorm can strip granules from asphalt shingles across an entire roof, and those granules protect the asphalt layer from UV exposure and moisture. Once they are gone, the shingles degrade faster and the roof's remaining lifespan shortens noticeably. The article recommends having the roof inspected promptly after a significant hail event rather than waiting to see if problems develop.

Roofing Expert Joe Ray's insights inform the article's section on moss and algae growth, which are common in shaded areas of a roof where moisture lingers. Moss holds moisture against the shingle surface and accelerates deterioration. North-facing roof sections in particular can develop biological growth in neighborhoods with significant tree coverage.

Roofing Expert Joe Ray is featured in the article's guidance that homeowners schedule an inspection every two to three years and after any major storm. Routine maintenance, the article explains, is far less costly than premature replacement, and for homeowners navigating the demanding conditions that affect roof lifespan Michigan winters produce, a proactive approach makes a meaningful financial difference over time.

How Long Does a Roof Last in Michigan, and What Shortens Its Lifespan? features insights from Joe Ray, Roofing Expert of Grand Haven, Michigan, in HelloNation.

About HelloNation

HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative "edvertising" approach that blends educational content with storytelling, HelloNation delivers expert-driven, good-news articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

DONOSTIA / SAN SEBASTIÁN, Spain, Oct. 19, 2026 /PRNewswire/ -- Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) gene therapy manufacturing, a subsidiary of AskBio, Inc. within the Bayer Group, today announced that Chief Executive Officer (CEO) Jimmy Vanhove will transition to a new role leading the development and expansion of Bayer's U.S. Pharmaceutical Product Supply Network based in New Albany, Ohio. In his new position, Jimmy will join the Pharmaceuticals Division's Product Supply Leadership Team. Angela Ochoa Chico has been appointed as his successor and will join Viralgen as CEO, from her current role at Bayer, effective January 1, 2027. She is an accomplished executive with extensive international leadership experience in pharmaceutical manufacturing and operations.

During Jimmy's four years leading the company, Viralgen has evolved from an emerging contract development and manufacturing organization (CDMO) into a market-leading AAV-specialist CDMO, supporting gene therapy programs from early development through commercial-scale manufacturing. Over this period, the company expanded its facilities, infrastructure, and process development capabilities, becoming a fully integrated, end-to-end CDMO with a strong portfolio of more than 70 customers and partners worldwide.

This progress has been driven by a strong quality mindset, operational reliability, and continuous improvement, with sustainability integrated into Viralgen's growth. Throughout, the company has remained focused on its purpose: bringing life-changing gene therapies closer to patients. From supporting gene therapy manufacturing for market-leading global pharmaceutical companies to more than 15 ultra-rare disease foundations, Viralgen remains committed to people living with rare diseases and the families who support them.

Today, Viralgen employs more than 450 professionals in San Sebastián, Spain, and operates one of the world's largest facilities dedicated to manufacturing AAV-based gene therapies, with integrated capabilities spanning process development, clinical and commercial production, quality control, and fill-finish.

"It has been a privilege to lead Viralgen through this transformative period," said Jimmy Vanhove. "I am especially proud that, as Viralgen has grown, we have remained committed to people living with both common and rare diseases, as well as the patient foundations that represent them. I am confident that Angela will build on this legacy and lead Viralgen into its next exciting chapter."

Angela Ochoa Chico brings nearly twenty years of international experience across pharmaceutical operations, quality, manufacturing, strategy, and organizational transformation. She comes to Viralgen from her role as Product Supply Strategy & Excellence Lead at the Pharmaceuticals Division of Bayer where she has helped shape global manufacturing strategy, strengthen organizational capabilities and drive performance across the Product Supply network. Earlier in her career, she led manufacturing and quality organizations in Mexico and held global roles spanning operations, regulatory affairs, supply chain, and strategic network management.

"I am delighted to join Viralgen at such an important stage in its evolution," said Angela Ochoa Chico. "Viralgen has built an outstanding reputation for scientific excellence, quality, and innovation, supported by an exceptionally talented team. I look forward to building on these strong foundations, advancing our manufacturing capabilities, and further strengthening Viralgen's position as a trusted gene therapy manufacturing partner, guided by a clear purpose to help bring transformative therapies to the patients who need them. Over the coming months, I will work closely with Jimmy and the Viralgen team to ensure a smooth transition into the CEO role."

About Viralgen

Viralgen is a leading Contract Development and Manufacturing Organization (CDMO) specializing exclusively in adeno-associated virus (AAV)-based cell and gene therapies. Founded in 2017 as a subsidiary of AskBio, Inc. within the Bayer AG group, Viralgen delivers end-to-end support from early development to large-scale commercial manufacturing. Leveraging their proprietary Pro10™ suspension cell line and Aava™ manufacturing platform, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes. Located in San Sebastian, Spain, its state-of-the-art facility features three cGMP suites with 2,000-liter capacities each, certified by the AEMPS and integrates services including plasmid production, process optimization, fill-finish, and in-house QC testing. With over 2,000 AAV batches produced, Viralgen provides reliable, efficient solutions to bringing life-changing gene therapies to patients with greater speed and consistency.  Learn more at viralgen.com and follow us on LinkedIn.

Share this article

FAIRFAX, Va., Oct. 19, 2026 /PRNewswire/ -- Allergy & Asthma Network will host the 12th annual USAsthma Summit, a free, one‑day event bringing together the nation's leading voices in asthma care, research, policy and lived experience. The Summit will take place Nov. 13, 2026, in Phoenix, Arizona, and via an interactive livestream, providing broad access to public health professionals, clinicians, asthma educators, respiratory therapists, patients, caregivers, advocates and community partners nationwide.

As asthma continues to affect millions of people in the United States and policymakers consider changes that could impact access to care, the USAsthma Summit provides a national forum to address emerging challenges and identify solutions. Through scientific and medical updates, policy discussions, practical strategies and patient perspectives, attendees will gain insights to help improve asthma care and outcomes in their communities.

The USAsthma Summit coincides with the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, creating opportunities for additional engagement among attendees, speakers and leaders in allergy, asthma and immunology.

Speakers and Sessions

The 2026 program features leaders across medicine, public and environmental health, behavioral health, patient advocacy and lived experience.

- The Asthma Landscape in the United States, Cherie Zachary, MD, FACAAI, President, President of the American College of Allergy, Asthma & Immunology (ACAAI)

- Creating Asthma-Friendly Environments: Action, Innovation and Leadership, Matthew Hiester, Environmental Protection Agency (EPA)

- Integrating Evidence-Based Behavioral Health into Asthma Care, Amanda Whitehouse, PhD

- Bridging Medicine, Research and Community: The Community Health Worker as a Healthcare Provider & Research Extender in Asthma Care, Floribella Redondo-Martinez, CCHW, BS

- SA Kids BREATHE: An Advocacy and Public Health Intervention, Mandie Svatek, MD

- The Great Digital Debate: How AI and Social Media Shape Asthma Care, Payel Gupta, MD and Michael Blaiss, MD

- Federal Mandates, Local Realities: Strategic Priorities to Advance Asthma Care Delivery in the 120th Congress, Miriam O'Day, Payel Gupta, MD and Ashley Strozier

- Patients at the Center of Asthma Care: Real Stories, Real Perspectives, Ashley Strozier, Clarissa Ruffin and Richard Redondo

Who Should Attend?

Allergy & Asthma Network's USAsthma Summit welcomes anyone committed to improving asthma outcomes, including community health workers, public health professionals, asthma coalition members, clinicians across specialties, advocates, people living with asthma and caregivers.

"The USAsthma Summit brings together diverse voices from across the asthma community to share ideas, address challenges and identify solutions," said Lynda Mitchell, CEO of Allergy & Asthma Network. "This year's program highlights emerging science, policy developments, patient perspectives and practical strategies that will help improve care and outcomes for people with asthma."

Registration is free for both in-person and virtual attendees.

To register: https://allergyasthmanetwork.formstack.com/forms/usasthmasummit2026

For full event details: https://allergyasthmanetwork.org/news/usasthma-summit-2026/

For Media

Members of the media are encouraged to arrange interviews with speakers and Allergy & Asthma Network leadership before the Summit. Journalists interested in on-site coverage should contact Jennifer Wilson using the information below. Allergy & Asthma Network representatives are available for interviews, background conversations and story development.

Jennifer Wilson | 571-395-8909 | [email protected]

About Allergy & Asthma Network

Founded in 1985, Allergy & Asthma Network is the leading nonprofit outreach, education, advocacy and research organization for people living with asthma, allergies and related conditions. Our mission is simple yet profound: to advance patient-centered research and advocate for better outcomes, access to care, education, and treatments that lead to improved health and quality of life. We specialize in making medically accurate information understandable to all, promoting evidence-based care, and fostering collaboration among patients, clinicians, researchers, advocates and policymakers. Learn more at AllergyAsthmaNetwork.org.

SOURCE Allergy & Asthma Network

Share this article

NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; "Lindblad"; the "Company"), a global provider of expedition cruises and adventure travel experiences, will report 2026 third quarter financial results on Tuesday, November 3, 2026, before the market opens, and will host an audio conference webcast to discuss the results at 9:00 am Eastern Time.

The webcast can be accessed on the Company's website at investors.expeditions.com, or at https://events.q4inc.com/attendee/416185057.

To participate in the Q&A, use the analyst registration to receive a unique passcode, https://events.q4inc.com/analyst/416185057?pwd=BmWfj6ho.

The conference can also be accessed by phone, dial-in numbers by country available at https://help.events.q4inc.com/eahc/international-dial-in-numbers, meeting ID 416185057.

Replays will be available at investors.expeditions.com within 48 hours of its completion.

The earnings release will be available in the investor relations section of the Company's website at investors.expeditions.com.

About Lindblad Expeditions

Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; the "Company") is a leader in global expedition travel, offering immersive, educational journeys that span all seven continents through its eight pioneering brands. Driven by a passion for the planet and the belief that there is always more to be discovered, the Company leads travelers to the farthest reaches of the world with an expansive portfolio of ship- and land-based expeditions. In collaboration with National Geographic, Lindblad Expeditions operates and sells the National Geographic-Lindblad Expeditions co-brand, which offers ship-based voyages that allow guests to explore remote destinations alongside scientists and naturalists, and with state-of-the-art exploration tools. In addition to its renowned modern expedition cruises, the Company's award-winning land-based brands—Natural Habitat Adventures, Off the Beaten Path, DuVine Cycling + Adventure Co., Classic Journeys, Wineland-Thomson Adventures, White Desert and Echo Charlie—provide extraordinary wildlife, cultural, and adventure-focused experiences. Together, these brands connect travelers with some of the planet's most inspiring natural and cultural landscapes, fostering a deep appreciation for the world.

To learn more about Lindblad Expeditions Holdings, Inc., its growing portfolio of brands, and the Company's commitment to responsible exploration, visit investors.expeditions.com.

SOURCE Lindblad Expeditions Holdings, Inc.

Share this article

Jackson to lead organic and inorganic growth initiatives, strategic partnerships and corporate development as the Company advances its life sciences and therapeutics platforms

TORONTO, Oct. 19, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the appointment of Angus Jackson as Managing Director of Corporate Development. In this role, Mr. Jackson will assist in the Company's organic and lead the inorganic growth initiatives, with responsibility for advancing strategic partnerships, evaluating acquisition and investment opportunities, and supporting the Company's long-term commercial and corporate development strategy.

Mr. Jackson brings a multidisciplinary background spanning investment banking, corporate law, business strategy and operating experience in the life sciences sector. Most recently, he served as an investment banker at Outcome Capital, a Boston-based boutique investment bank focused on the healthcare and life sciences industries. At Outcome Capital, he advised companies across pharmaceuticals, pharmaceutical services, medical technology and healthcare services on mergers and acquisitions, capital raising and strategic transactions.

Prior to his investment banking career, Mr. Jackson held corporate development and operating responsibilities at a family-owned contract manufacturing business serving the pharmaceutical and life sciences industries, where he was involved in strategic initiatives and acquisitions. Vector believes his combination of transaction execution experience and direct operating exposure positions him to help the Company pursue growth opportunities across its business and technology platforms.

Mr. Jackson holds a Master of Business Administration from the University of Virginia Darden School of Business, a Juris Doctor from the University of Georgia School of Law, and a Master of Laws (LL.M.) from Duke University School of Law, with a focus on law and entrepreneurship. His academic and professional background combines financial analysis, transaction structuring, corporate strategy, entrepreneurship and legal expertise.

Role and Priorities

In his new role, Mr. Jackson will focus on identifying and executing opportunities to accelerate Vector's growth, including commercial expansion, strategic alliances, business development initiatives and selective mergers and acquisitions. He will also work with Company leadership to evaluate opportunities that complement Vector's existing capabilities and support the development and commercialization of its therapeutic delivery technologies, medical devices and peptide-related offerings.

"Disciplined corporate development is essential to turning Vector's technology platforms into lasting commercial value," said Tommy Thompson, Chairman of Vector Science and Therapeutics and former U.S. Secretary of Health and Human Services. "Angus's background in healthcare investment banking, law and pharmaceutical manufacturing gives the Company the expertise to evaluate and execute strategic opportunities with rigor, and we are pleased to welcome him to the team."

"Angus brings a rare combination of transaction experience and hands-on operating knowledge of pharmaceutical manufacturing, which is exactly what Vector needs as we scale," said Russell Starr, President of Vector Science and Therapeutics. "As we evaluate partnerships and acquisitions that complement our delivery technologies and peptide platform, his ability to identify, structure and execute the right opportunities will be an important asset to the Company and our shareholders."

"I am excited to join Vector at an important stage in the Company's development," said Angus Jackson, Managing Director of Corporate Development. "Vector has an opportunity to build on its existing technology platforms, deepen strategic partnerships, and pursue new avenues for commercial growth. I look forward to working with the team to execute a disciplined growth strategy that combines organic expansion with targeted strategic transactions and partnerships."

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing drug delivery technology and pharma-grade peptide manufacturing for the sports medicine, regenerative medicine, and pain management markets. Vector's peptides are pharma-grade, not research-grade: they are manufactured under cGMP, FDA, and ISO-compliant conditions, Rx-labeled, and sold directly to physicians for physician use, rather than distributed through the research-only channels associated with research-grade material. The Company's product and intellectual property portfolio is focused on advanced transdermal delivery, precision catheter systems, localized pain management, pancreatic oncology, and smart wound care. Vector is headquartered in Mequon, Wisconsin. For more information, visit https://vectorscience.co/.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding Mr. Jackson's anticipated role and responsibilities, the Company's growth strategy, and the Company's intention to pursue commercial expansion, strategic partnerships, business development initiatives, investments and acquisitions. Forward-looking information is based on management's current expectations and assumptions and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied, including the risk that the Company does not identify suitable partnerships, investments or acquisitions, that any such transactions are not completed on acceptable terms or at all, that required financing or regulatory and stock exchange approvals are not obtained, or that the anticipated benefits of any transaction are not realized. Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake any obligation to update forward-looking information except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Vector Sciences & Therapeutics

Share this article

PROPOSED SETTLEMENT OF DERIVATIVE AND CLASS ACTION, SETTLEMENT HEARING, AND RIGHT TO APPEAR ANNOUNCED IN ATLAS STOCKHOLDER CLASS ACTION LITIGATION

PHILADELPHIA, Oct. 19, 2026 /PRNewswire/ -- The following statement is being issued by Kroll Settlement Administration LLC regarding Ayers v. Brigham, Atlas Energy Solutions.

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE AND CLASS ACTION, SETTLEMENT HEARING, AND RIGHT TO APPEAR

TO: All (1) record holders and beneficial owners of Atlas Energy Solutions, Inc. ("Atlas" or the "Company") Class A common stock (NYSE: "AESI") as of October 2, 2023; and (2) Current Stockholders of Atlas common stock.1

PLEASE READ THIS SUMMARY NOTICE CAREFULLY. YOUR RIGHTS WILL BE AFFECTED BY A DERIVATIVE AND CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, pursuant to an Order of the Court of Chancery of the State of Delaware (the "Court"), that the above-captioned derivative and class action lawsuit (the "Action") is pending in the Court.

YOU ARE ALSO NOTIFIED that Patrick Ayers ("Plaintiff"), individually and on behalf of the Class and derivatively on behalf of Atlas, has reached a proposed settlement with defendants Ben M. Brigham, Douglas G. Rogers, A. Lance Langford, Stacy Hock, Stephen Cole, Atlas Sand Holdings, LLC, Atlas Sand Holdings II, LLC, Atlas Sand Management Company, LLC, and Atlas Sand Management Company II, LLC (collectively, "Defendants," and together with Plaintiff and Atlas, the "Parties") for $17,000,000 in cash (the "Settlement"). The terms of the Settlement are stated in the Stipulation and Agreement of Settlement, Compromise, and Release among the Parties, dated September 10, 2026 (the "Stipulation"), a copy of which is available at www.AtlasStockholderClassActionLitigation.com. If approved by the Court, the Settlement will resolve all claims in the Action against Defendants, and the Action will be dismissed with prejudice.

A hearing (the "Settlement Hearing") will be held on December 18, 2026, at 1:30 p.m. E.T., before The Honorable J. Travis Laster, Vice Chancellor, either in person at the Court of Chancery of the State of Delaware, New Castle County, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware 19801, or remotely by Zoom (in the discretion of the Court), to, among other things: (i) determine whether to certify the Settlement Class, appoint Plaintiff as Settlement Class representative, and appoint Plaintiff's Counsel as Settlement Class counsel (in each instance, for Settlement purposes); (ii) determine whether the Court should approve the proposed Settlement as fair, reasonable, and adequate to the Settlement Class and Atlas; (iii) determine whether a Judgment substantially in the form attached as Exhibit D to the Stipulation should be entered dismissing the Action with prejudice against Defendants and granting the Releases set forth in the Stipulation; (iv) determine whether the proposed plan of allocation of the Settlement Fund is fair and reasonable, and should therefore be approved; (v) determine whether the application by Plaintiff's Counsel for an award of attorneys' fees and litigation expenses ("Fee and Expense Award"), and any incentive award to Plaintiff to be paid solely from any Fee and Expense Award, should be approved; (vi) hear and determine any objections to the Settlement or Plaintiff's Counsel's application for an award of attorneys' fees and litigation expenses and any incentive award to Plaintiff; and (vii) consider any other matters that may properly be brought before the Court in connection with the Settlement. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the Settlement website, www.AtlasStockholderClassActionLitigation.com.

If you are a member of the Settlement Class or a Current Stockholder, your rights will be affected by the pending Action and the Settlement. If you are a member of the Settlement Class, you may be entitled to share in the Net Settlement Fund. If you have not yet received the full Notice, you may obtain a copy of the Notice by contacting the Notice Administrator at Atlas Stockholder Class Action Litigation, c/o Kroll Settlement Administration LLC, P.O. Box 225391, New York, NY 10150-5391. A copy of the Notice can also be downloaded from the Settlement website, www.AtlasStockholderClassActionLitigation.com.

If the Settlement is approved by the Court and the Effective Date occurs, the Net Settlement Fund will be distributed on a pro rata basis to "Settlement Class" members in accordance with the proposed Plan of Allocation stated in the Notice or such other plan of allocation as is approved by the Court. Under the proposed Plan of Allocation, all Settlement Class members who held or beneficially owned shares of Former Atlas Class A common stock as of the Closing on October 2, 2023, and whose shares of Former Atlas Class A common stock were exchanged for shares of New Atlas Class A common stock in the Reorganization (their "Eligible Shares") will be eligible to receive a pro rata payment from the Net Settlement Fund equal to the product of (i) the number of Eligible Shares held by the Settlement Class member and (ii) the "Per-Share Recovery" for the Settlement, which will be determined by dividing the total amount of the Net Settlement Fund by the total number of Eligible Shares. As explained in further detail in the Notice, pursuant to the Plan of Allocation, payments from the Net Settlement Fund to Settlement Class members will be made through the same accounts through which Settlement Class members received their shares of New Atlas Class A common stock in the Reorganization. Settlement Class members do not need to submit a claim form to receive a payment from the Settlement.

Settlement Class members and Current Stockholders have the right to object to the Settlement. Any objections to the proposed Settlement, the proposed Plan of Allocation, or Plaintiff's Counsel's application for the Fee and Expense Award and any incentive award to Plaintiff in connection with the Settlement must be filed with the Register in Chancery in the Court of Chancery of the State of Delaware and delivered to Plaintiff's Counsel and Defendants' counsel such that they are received no later than November 25, 2026, in accordance with the instructions set forth in the Notice.

Please do not contact the Court or the Office of the Register in Chancery regarding this notice. All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Notice Administrator or Plaintiff's Counsel.

Requests for the Notice should be made to the Notice Administrator:

Atlas Stockholder Class Action Litigation

c/o Kroll Settlement Administration LLC

P.O. Box 225391

New York, NY 10150-5391

Inquiries, other than requests for the Notice, should be made to Plaintiff's Counsel:

Kimberly Evans

BLOCK & LEVITON LLP

222 Delaware Avenue, Suite 1120

Wilmington, DE 19801

[email protected]

Mark Richardson

LABATON KELLER SUCHAROW LLP

222 Delaware Avenue, Suite 1510

Wilmington, DE 19801

[email protected]

Jeremy Friedman

FRIEDMAN & TEJTEL PLLC

493 Bedford Center Road, Suite 2D

Bedford Hills, NY 10507

[email protected]

Dated: October 6, 2026

BY ORDER OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE

1 Any capitalized terms used in this Summary Notice that are not otherwise defined in this Summary Notice shall have the meanings given to them in the full Notice of Proposed Settlement of Derivative and Class Action, Settlement Hearing, and Right to Appear (the "Notice"), available at www.AtlasStockholderClassActionLitigation.com.

SOURCE Kroll Settlement Administration LLC

Share this article